SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.